With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Outcomes of the Phase 3 OPTIMIZE-2 trial were reported this month in JAMA Onc assessing de-intensification of bisphosphonate therapy. 412 women with breast cancer metastatic to bone already receiving zoledronic acid or pamidronate (and s/p at least 9 monthly doses) were randomized to continue receiving zoledronic acid infusions every 4 versus 12 weeks. The number of and median time to first skeletal-related events were not inferior in the experimental group receiving infusions one-third as often. Why does this matter? ASCO currently recommends routine use of a bone-modifying agent every 3-4 weeks indefinitely for these patients. And with women with metastatic breast cancer living longer than ever, careful consideration of long-term toxicities are more pertinent than ever. As we get smarter at treating cancer, we have to get smarter at treating survivors: and this is a bone-fide step in the right direction.